{{Rsnum
|rsid=5030062
|Gene=KNG1
|Chromosome=3
|position=186736391
|Orientation=plus
|GMAF=0.3499
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Gene_s=KNG1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 37.2 | 48.7 | 14.2
| HCB | 54.0 | 36.5 | 9.5
| JPT | 57.5 | 35.4 | 7.1
| YRI | 52.7 | 36.3 | 11.0
| ASW | 54.4 | 35.1 | 10.5
| CHB | 54.0 | 36.5 | 9.5
| CHD | 50.5 | 39.4 | 10.1
| GIH | 46.5 | 41.6 | 11.9
| LWK | 42.7 | 49.1 | 8.2
| MEX | 25.9 | 63.8 | 10.3
| MKK | 34.0 | 53.8 | 12.2
| TSI | 31.4 | 52.0 | 16.7
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs5030062
|Name_s=
|Gene_s=KNG1
|Feature=Intron
|Evidence=PubMed ID:19584173
|Annotation=This study investigated aldosterone response to two antihypertensive drugs with the result that the existence of one or more variants in the KNG1gene influences interindividual variation in aldosterone response. The SNPs rs5030062 and rs698078 were significantly associated in European-American responders to the diuretic (p=0.05 and p=0.01) and European-American responders to the angiotensin receptor blocker (p=0.04 and p=0.02).
|Drugs=candesartan; hydrochlorothiazide
|Drug Classes=ANTIHYPERTENSIVES
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA164920406
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs5030062
|overall_frequency_n=47
|overall_frequency_d=126
|overall_frequency=0.373016
|n_genomes=33
|n_genomes_annotated=0
|n_haplomes=39
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}